北新路橋(002307.SZ):發行股份、可轉債購買資產事項獲證監會核准批覆
格隆匯6月4日丨北新路橋(002307.SZ)公佈,公司近日收到中國證監會核發的《關於核准新疆北新路橋集團股份有限公司向新疆生產建設兵團建設工程(集團)有限責任公司發行股份、可轉換公司債券購買資產並募集配套資金的批覆》(證監許可[2020]1005號),核准公司向新疆生產建設兵團建設工程(集團)有限責任公司發行約1.56億股股份、108萬張可轉換債券購買相關資產;核准公司發行股份募集配套資金不超過約7.997億元;發行可轉換公司債券募集配套資金不超過1.5億元,批覆自下發之日起12個月內有效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.